Pediatric ethics
Executive Summary
FDA's Pediatric Advisory Subcommittee on Pediatric Ethics will meet June 9-10 to discuss clinical investigations that involve greater than minimal risk but present the prospect of direct benefits to individual subjects. The June 9 discussion will be illustrated with hypothetical cases of research involving HIV vaccines in adolescents and controlled trials of inhaled corticosteroids in children with asthma, and the June 10 discussion with a hypothetical case of research using stem cells for treating periventricular white matter injury in children
You may also be interested in...
Scotland's MGB Plots Phase III For Promising Antibacterial
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AstraZeneca Vaccine May Only Gain EU Approval In Under 70s
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
Moment Of Truth In EU For Amarin’s ‘Multi-Billion-Dollar Opportunity’ Drug
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: